Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
0.6256
-0.0341 (-5.17%)
At close: Jul 25, 2025, 4:00 PM
0.6165
-0.0091 (-1.45%)
After-hours: Jul 25, 2025, 7:31 PM EDT
Century Therapeutics Stock Forecast
IPSC's stock price has decreased by -73.71% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts that cover Century Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $3.33, which forecasts a 432.29% increase in the stock price over the next year. The lowest target is $2 and the highest is $6.
Price Target: $3.33 (+432.29%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 16, 2025.
Analyst Ratings
The average analyst rating for Century Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $7 → $6 | Strong Buy | Maintains | $7 → $6 | +859.08% | May 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $2 | Strong Buy | Maintains | $5 → $2 | +219.69% | Apr 3, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Mar 28, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 → $7 | Strong Buy | Maintains | $11 → $7 | +1,018.93% | Mar 24, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $12 → $5 | Strong Buy | Maintains | $12 → $5 | +699.23% | Mar 21, 2025 |
Financial Forecast
Revenue This Year
111.36M
from 6.59M
Increased by 1,590.09%
Revenue Next Year
n/a
from 111.36M
EPS This Year
-0.28
from -1.61
EPS Next Year
-1.44
from -0.28
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 114.7M | n/a | n/a | ||
| Avg | 111.4M | n/a | n/a | ||
| Low | 107.0M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,640.2% | - | - | ||
| Avg | 1,590.1% | - | - | ||
| Low | 1,523.6% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.14 | -0.64 | -1.31 |
| Avg | -0.28 | -1.44 | -1.45 |
| Low | -0.35 | -1.75 | -1.56 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.